Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, with reference to the NICE draft guidance issued on 7 April 2022 on sacituzumab govitecan, Trodelvy, what steps his Department is taking to help ensure that people with triple negative breast cancer can access treatment that could extend their lifespan.

The National Institute for Health and Care Excellence (NICE) has recommended several medicines for the treatment of patients with breast cancer, including triple-negative breast cancer, which are routinely available for National Health Service patients.

NICE is currently developing guidance on the use of Trodelvy (sacituzumab govitecan) for the treatment of unresectable triple-negative locally advanced or metastatic breast cancer in adults after two or more systemic therapies. In June 2022, NICE’s Appraisal Committee will consider its recommendations following responses to the recent consultation on its draft guidance. If Trodelvy is recommended in NICE’s final draft guidance, it will be eligible for funding through the Cancer Drugs Fund. NICE expects to issue final guidance on Trodelvy in August 2022.